Suppliers and packagers for PROVAYBLUE

PROVAYBLUE

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Provepharm Sas	PROVAYBLUE	methylene blue	SOLUTION;INTRAVENOUS	204630	NDA	American Regent, Inc.	0517-0125-05	5 AMPULE in 1 CARTON (0517-0125-05) / 2 mL in 1 AMPULE (0517-0125-01)	2020-04-08
Provepharm Sas	PROVAYBLUE	methylene blue	SOLUTION;INTRAVENOUS	204630	NDA	American Regent, Inc.	0517-0371-05	5 VIAL, SINGLE-DOSE in 1 CARTON (0517-0371-05) / 2 mL in 1 VIAL, SINGLE-DOSE (0517-0371-01)	2020-04-08
Provepharm Sas	PROVAYBLUE	methylene blue	SOLUTION;INTRAVENOUS	204630	NDA	American Regent, Inc.	0517-0374-05	5 AMPULE in 1 CARTON (0517-0374-05) / 10 mL in 1 AMPULE (0517-0374-01)	2016-04-08

Suppliers for Provayblue (methylene blue): key manufacturers, contract supply, and procurement implications

Last updated: May 23, 2026

Executive summary: Provayblue (methylene blue) is sourced from established small-molecule API and finished-dosage manufacturers. In US commerce, supply is anchored by brand holders and authorized generic/finished-dose producers listed in FDA drug product records and distributor networks; procurement risk concentrates around API availability, sterile-manufacturing capacity for injection, and regulatory batch release controls. Competitive dynamics depend on strength-specific formulations (injection vs oral/other strengths where applicable), plus whether supply is for US distribution, hospital purchase, or direct-to-provider channels.

Which companies supply Provayblue (methylene blue) in the US?

Direct answer: Identify the specific FDA-listed product(s) under the Provayblue brand name and map the listed applicants/manufacturers (drug product and API) to distributors and wholesalers that physically supply the US market.

What to check in FDA drug labeling records

• Drug product labeler/manufacturer (finished dosage): the entity responsible for the approved product for the marketed strength/formulation.
• Applicant/holder (NDA/ANDA reference): often different from the physical manufacturer.
• Manufacturer of drug substance (API): methylene blue supply can shift across supplier networks without changing the marketed label.
• CGMP release and contract manufacturing: injection products typically require tighter controls, reducing the number of qualified sterile-capable sites.

API supplier landscape for methylene blue

Methylene blue (CAS 61-73-4) is a legacy dye-based pharmaceutical ingredient. API supply commonly comes from:

• specialty chemical producers that run dye intermediates to API grade,
• pharmaceutical-grade chemical manufacturers with controlled impurities and documentation for regulatory markets,
• contract manufacturers that supply to multiple brand labels.

Procurement for finished injectable methylene blue is generally more constrained than oral forms due to sterile filling, container-closure compatibility, and batch release testing.

What suppliers provide Provayblue injection vs oral formulations?

Direct answer: Injection supply chains are narrower and more exposed to sterility and aseptic fill/finish capacity limits; oral/solid supply chains are typically broader.

Injection (hospital use) supplier constraints

• Sterile manufacturing capacity: aseptic processing and endotoxin/sterility testing throughput.
• Container-closure system qualification: glass vials and rubber closures require compatibility studies for methylene blue solutions.
• Batch release timelines: analytic method validation and stability program completion impact lead times.
• API spec tightening: methylene blue impurities and absorbance-related specifications drive supplier qualification.

Oral/solid forms (if marketed under Provayblue)

If Provayblue is distributed in oral/solid strengths in a given market, supply constraints usually shift toward:

• uniformity and dissolution testing,
• excipient sourcing consistency,
• tablet/capsule packaging line capacity.

How do distributors and wholesalers affect Provayblue availability?

Direct answer: Distribution does not change the underlying product manufacturer, but it affects allocation, lead times, and substitution risk when API shortages or sterile capacity constraints occur.

Typical US channel structure

• Wholesalers and group purchasing organizations (GPOs): set ordering cadence and can drive allocation decisions.
• Hospital procurement systems: often require product substitution approval and specific NDC sourcing.
• Direct-to-provider fulfillment: used when wholesalers face constrained inventories.

Operationally, the “supplier” for procurement can mean either:

1. the NDA/ANDA-listed manufacturer of the branded product, or
2. the commercial distributor shipping finished goods.

What patent and exclusivity factors change supplier eligibility for methylene blue?

Direct answer: Methylene blue is generally treated as an old, small-molecule active with limited new exclusivity leverage in many markets. Supplier entry usually depends more on regulatory listing (NDC availability), manufacturing qualification, and quality system readiness than on patent barriers.

Typical effects on supply

• Patent estates on specific formulations, methods of use, or packaging can limit label-compatible competitors.
• In practice, multi-source entry increases when:
  • finished-dose regulatory pathways are available,
  • API supply is stable,
  • sterile manufacturing slots are available.

What are the main regulatory and quality requirements that determine suppliers?

Direct answer: For Provayblue injections, supplier approval is dominated by CGMP performance, sterile processing compliance, and consistent batch release.

Key supplier requirements

• Sterile manufacturing compliance: aseptic technique controls, environmental monitoring, sterility assurance testing.
• Stability and shelf-life documentation: real-time and accelerated stability data for methylene blue solutions.
• Analytical method robustness: assay, impurities, pH/appearance, and particulate testing.
• Traceability of API: CoA controls and batch genealogy.

How many suppliers can typically meet Provayblue (methylene blue) demand?

Direct answer: For injectable products, qualified suppliers are fewer than for many non-sterile drugs because sterile fill-finish is a capacity-limited step and quality requirements are high. For methylene blue as an API, multiple chemical producers can supply drug substance, but not all are approved for pharmaceutical-grade finished dosage manufacture.

What generic or alternative methylene blue products compete with Provayblue?

Direct answer: Competition is usually from authorized generics or labeled alternative methylene blue injectable products at the same route of administration, plus pharmacy-manufactured or compounded supply in certain settings where commercial product is scarce.

What to compare for procurement

• NDC and strength
• Solution pH and excipient package
• Sterility format and container size
• Labeling indications and dosing guidance
• Availability and allocation history through wholesalers

Who should procurement teams treat as “true suppliers” for Provayblue?

Direct answer: The true supply chain is identified by:

1. the finished drug product manufacturer listed for the NDC under Provayblue, and
2. the manufacturer of drug substance supplying the validated API route, plus
3. the distribution parties that hold inventory for the delivery points you manage.

These entities are what drive batch timing, allocation outcomes, and substitution acceptability.

Key takeaways

• Provayblue (methylene blue) supply in the US is determined by the finished-dose manufacturer and the qualified sterile manufacturing sites for injectable product.
• API availability can be broader than finished-dose availability; injection supply is more constrained due to sterility and aseptic fill-finish.
• Procurement risk is dominated by sterile capacity, batch release timelines, and API impurity/spec conformance.
• Competitive supply is driven more by regulatory listing and manufacturing qualification than by exclusivity barriers for many methylene blue products.

FAQs

1. What determines whether a new supplier can manufacture methylene blue injection for US distribution?
   CGMP compliance for sterile manufacture, validated analytical methods, stability and shelf-life support, and FDA-facing quality system readiness for batch release.

2. How can procurement teams reduce risk of Provayblue injection allocation?
   Use multiple stocking channels tied to specific NDCs, manage lead times around sterile fill/finish cycles, and qualify alternate labeled methylene blue sources.

3. Does methylene blue API sourcing affect injection product stability or release?
   Yes, API impurity profile and spec conformance can change pH/appearance and impurity limits, impacting batch release and stability outcomes.

4. Are compounded methylene blue products a substitute when Provayblue is scarce?
   In some settings, compounded supply can fill gaps, but procurement must handle variability in quality controls and labeled equivalence.

5. Which step usually causes the largest delays for Provayblue injection supply?
   Aseptic sterile fill-finish capacity and subsequent batch testing/release are typically the tightest bottlenecks versus non-sterile processing.

References

1. US Food and Drug Administration. Drug Databases: Drugs@FDA. https://www.accessdata.fda.gov/scripts/cder/daf/
2. FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. https://www.accessdata.fda.gov/scripts/cder/ob/
3. FDA. Drug Quality and Labeling Information. https://www.fda.gov/drugs/drug-quality-and-labeling-information